Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial Meeting Abstract
| Authors: | Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothe, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T. W.; Coccia-Portugal, M. A.; Di Cosimo, S.; de Azambuja, E.; de la Pena, L.; Nuciforo, P.; Armour, A.; Eidtmann, H.; Baselga, J.; Piccart, M.; Loi, S. |
| Abstract Title: | Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial |
| Meeting Title: | 18th European Cancer Conference (ECCO 18) |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2015 Sep 25-29 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S269 |
| Language: | English |
| ACCESSION: | WOS:000361887401182 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)30764-X |
| Notes: | Meeting Abstract: 1811 -- Source: Wos |
